Ubiquitin carboxyl-terminal hydrolase 28
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein homooligomer Homooligomer Protein × 2 PDB declaration: dimeric(2) Consistent with protein copy count | Chain A; UniProt 149–458 Chain A; UniProt 529–707 Chain B; UniProt 149–458 Chain B; UniProt 529–707 | Not recorded | CL CHLORIDE ION × 1 DMS DIMETHYL SULFOXIDE × 1 WF0 2-[[5-bromanyl-2-[[4-fluoranyl-3-(trifluoromethyl)phenyl]methoxy]phenyl]methylamino]ethanol × 2 | X-RAY DIFFRACTION X-ray crystallization conditions:VAPOR DIFFUSION, HANGING DROP;293 K;0.5 M sodium malonate pH 6.0 0.1 M sodium citrate pH 5.0 | Resolution 2.76 Å R-free 0.241 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 8P1P | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 2LVA NMR solution structure of the N-terminal domain of human USP28, Northeast structural genomics consortium target HT8470A Deposited 2012-06-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
22–132(111 aa)
Fragment:UIM domain residues 22-132
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.5;298 K;Ionic strength (raw mmCIF value) 450;Pressure ambient
NMR sample composition
0.5 mM [U-13C; U-15N] protein, 10 mM mops, 450 mM sodium chloride, 10 uM ZnSO4, 1 mM DTT, 0.01 % NaN3, 1 mM benzamidine, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2MUU The Proteolytic Activity of Ubiquitin-specific Protease 28 Is Modulated by the N-terminal Domain Deposited 2014-09-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
1–120(120 aa)
Fragment:N-terminal Domain (UNP residues 1-120)
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.5;298.2 K;Ionic strength (raw mmCIF value) 0.15;Pressure 1
NMR sample composition
10 % D20, 90 % H20, 0.8-1.0 mM [U-15N] USP, 20 mM Na2HPO4/NaH2PO4, 100 mM NaCl, 2 mM DTT, 0.02 % NaNH3, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
10 % D20, 90 % H20, 0.8-1.0 mM [U-15N; U-13C] USP, 20 mM Na2HPO4/NaH2PO4, 100 mM NaCl, 2 mM DTT, 0.02 % NaNH3, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
100 % D20, 0.8-1.0 mM [U-15N; U-13C] USP, 20 mM Na2HPO4/NaH2PO4, 100 mM NaCl, 2 mM DTT, 0.02 % NaNH3, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 6H4H Usp28 catalytic domain variant E593D in complex with UbPA Deposited 2018-07-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
149–707(559 aa)
Chain B
149–707(559 aa)
|
Mutation:E593D Mutation:E593D | SO4 SULFATE ION × 1 AYE prop-2-en-1-amine × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;273 K;0.1 M Citrate pH 5.0
0.8 M Ammonium Sulfate
|
Resolution 3.50 Å R-free 0.280 |
| 6H4I Usp28 catalytic domain apo Deposited 2018-07-21 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
148–707(560 aa)
Chain C
148–707(560 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) Non-standard monomer:Yes (specific site not provided by mmCIF) | SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5;293 K;0.1 M citric acid pH 5.0
0.8 M Ammonium Sulfate
|
Resolution 3.22 Å R-free 0.196 |
| 6HEH Structure of the catalytic domain of USP28 (insertion deleted) Deposited 2018-08-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
149–399(251 aa)
Chain A
580–703(124 aa)
|
Mutation:;residues 400-579 replaced by GSGSGS,residues 400-579 replaced by GSGSGS,residues 400-579 replaced by GSGSGS,residues 400-579 replaced by GSGSGS ; Mutation:;residues 400-579 replaced by GSGSGS,residues 400-579 replaced by GSGSGS,residues 400-579 replaced by GSGSGS,residues 400-579 replaced by GSGSGS ; | EDO 1,2-ETHANEDIOL × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.6;291 K;12% (w/v) PEG 8000, 100 mM sodium chloride, 200 mM lithium sulfate, 100 mM MES pH 6.6
|
Resolution 2.26 Å R-free 0.216 |
| 6HEI Structure of the catalytic domain of USP28 (insertion deleted) bound to Ubiquitin-PA Deposited 2018-08-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
149–399(251 aa)
Chain A
580–703(124 aa)
|
Mutation:;residues 400-579 replaced by GSGSGS,residues 400-579 replaced by GSGSGS,residues 400-579 replaced by GSGSGS,residues 400-579 replaced by GSGSGS ; Mutation:;residues 400-579 replaced by GSGSGS,residues 400-579 replaced by GSGSGS,residues 400-579 replaced by GSGSGS,residues 400-579 replaced by GSGSGS ; | EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8;291 K;22% (w/v) PEG 3350, 300 mM potassium sodium tartrate
|
Resolution 1.64 Å R-free 0.214 |
| 6HEJ Structure of human USP28 Deposited 2018-08-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
149–703(555 aa)
Chain B
149–703(555 aa)
|
Not recorded | SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;291 K;0.8 M ammonium sulfate, 100 mM sodium citrate pH 5.5
|
Resolution 2.79 Å R-free 0.286 |
| 6HEK Structure of human USP28 bound to Ubiquitin-PA Deposited 2018-08-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
149–703(555 aa)
Chain C
149–703(555 aa)
|
Not recorded | PG4 TETRAETHYLENE GLYCOL × 2 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.4;291 K;8% (w/v) PEG 3350, 200 mM ammonium acetate and 100 mM sodium citrate pH 5.4
|
Resolution 3.03 Å R-free 0.237 |
| 7TUO Crystal structure analysis of human USP28 complex with a compound Deposited 2022-02-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
149–399(251 aa)
Chain A
580–703(124 aa)
|
Not recorded | KL9 7-amino-N-(2-{4-[(1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl]phenyl}ethyl)-3-methylthieno[2,3-b]pyrazine-6-carboxamide × 2 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;1.4M Sodium maleic acid, pH 8.0
|
Resolution 1.96 Å R-free 0.203 |
| 8HJE Vismodegib binds to the catalytical domain of human Ubiquitin-Specific Protease 28 Deposited 2022-11-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
150–399(250 aa)
Chain A
580–703(124 aa)
|
Not recorded | VIS 2-chloranyl-~{N}-(4-chloranyl-3-pyridin-2-yl-phenyl)-4-methylsulfonyl-benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.4;291 K;0.1 M Bis-tris propane pH 6.4, 0.2 M potassium thiocyanate, 20% PEG3350 and 3% sucrose
|
Resolution 2.85 Å R-free 0.254 |
| 8P14 USP28 USP domain in complex with Vismodegib Deposited 2023-05-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
149–399(251 aa)
Chain A
580–698(119 aa)
|
Not recorded | VIS 2-chloranyl-~{N}-(4-chloranyl-3-pyridin-2-yl-phenyl)-4-methylsulfonyl-benzamide × 1 CL CHLORIDE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.05 M NaCl
0.1 M Li2SO4
0.1 M MES pH 6.4
14% PEG4000
|
Resolution 2.57 Å R-free 0.218 |
| 8P19 USP28 USP domain apo Deposited 2023-05-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
149–399(251 aa)
Chain A
580–698(119 aa)
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 CL CHLORIDE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.05M NaCl
0.1M Li2SO4
0.1M MES pH 6.4
14% PEG4000
|
Resolution 2.45 Å R-free 0.222 |
| 8P1Q USP28 in complex with FT206 Deposited 2023-05-12 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
149–458(310 aa)
Chain A
529–707(179 aa)
Chain B
149–458(310 aa)
Chain B
529–707(179 aa)
|
Not recorded | DMS DIMETHYL SULFOXIDE × 2 WFT 3-azanyl-N-[(2S)-6-[(1S,5R)-3,8-diazabicyclo[3.2.1]octan-3-yl]-1,2,3,4-tetrahydronaphthalen-2-yl]-6-methyl-thieno[2,3-b]pyridine-2-carboxamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.5 M Na-malonate, pH6.0
0.1M Na-citrate, pH 5.0
|
Resolution 2.79 Å R-free 0.235 |
| 9SUU USP28 USP domain in complex with T-10531 Deposited 2025-09-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
149–399(251 aa)
Chain A
580–698(119 aa)
|
Not recorded | CL CHLORIDE ION × 4 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 A1JQP ~{N}-[3-[[4-bromanyl-5-fluoranyl-2-[[(3~{S})-3-oxidanylpyrrolidin-1-yl]methyl]phenoxy]methyl]-2,4,5-tris(fluoranyl)phenyl]-2-chloranyl-4-methylsulfonyl-benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.4;293 K;0.05 M sodium chloride, 0.2 M lithium sulfate, 0.1 M MES pH 6.4, 14 % PEG6000
|
Resolution 2.75 Å R-free 0.245 |
14 other PDB entries and 14 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | UBP28_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A; PDBConstruct 2–311; UniProt 149–458 Author chain A; PDBConstruct 316–494; UniProt 529–707 Author chain B; PDBConstruct 2–311; UniProt 149–458 Author chain B; PDBConstruct 316–494; UniProt 529–707 |